Skip to main content

Table 2 Comparisons of patient characteristics, prescriptions of CRRT, and laboratory findings among the study groups at the time of CRRT initiation

From: Using additional pressure control lines when connecting a continuous renal replacement therapy device to an extracorporeal membrane oxygenation circuit

Characteristics

No line group

(n = 16)

Single line group

(n = 36)

Double line group

(n = 118)

P value

Age, years

59 (48–65)

54 (36–62)

58 (48–65)

0.241

Male

12 (75.0)

24 (66.7)

79 (66.9)

0.804

Body mass index, kg/m2

23 (21–26)

24.5 (22.5–27.4)

25.0 (22.1–28.0)

0.291

ECMO flow, L/min

3.5 (2.6–4.1)

3.5 (3.0–4.2)

3.8 (3.2–4.3)

0.192

Indication for CRRT

 Acute kidney injury

2 (12.5)

8 (22.2)

31 (26.3)

0.461

 Volume overload

6 (37.5)

15 (41.7)

59 (50.0)

0.492

 Metabolic acidosis

11 (68.8)

20 (55.6)

35 (29.7)

0.001†‡

Prescription of initial CRRT

 Blood flow, mL/min

150 (150–150)

150 (150–150)

150 (150–150)

0.013†

 CRRT dose, mL/kg/hr

40 (31–46)

36 (27–44)

32 (27–44)

0.062

 Dialysate flow, mL/hr

1250 (1000–1500)

1000 (1000–1500)

1000 (1000–1500)

0.033

 Replacement fluid flow, mL/hr

1250 (1000–1500)

1000 (1000–1500)

1000 (1000–1500)

0.041

 Prescribed fluid balance, mL/hr

0 (− 40–0)

0 (−40–0)

−20 (− 43–0)

0.189

Anticoagulation for CRRT

 Systemic heparin

9 (56.3)

22 (61.1)

76 (64.4)

0.792

 Regional heparin

0 (0.0)

0 (0.0)

0 (0.0)

–

 Regional nafamostat

5 (31.3)

4 (11.1)

3 (2.5)

< 0.001†

 Systemic argatroban

0 (0.0)

0 (0.0)

4 (3.4)

0.406

 None

4 (25.0)

12 (33.3)

37 (31.4)

0.833

Laboratory findings on CRRT initiation

 Blood urea nitrogen, mg/dL

28.2 (18.3–41.8)

29.7 (18.7–55.9)

38.9 (24.2–59.3)

0.105

 Creatinine, mg/dL

1.76 (1.42–2.27)

1.78 (1.23–2.95)

1.93 (1.26–3.07)

0.587

 Bicarbonate, mmol/L

18.1 (14.2–19.6)

14.7 (11–18.1)

18.9 (13.8–22)

0.034‡

 potassium, mmol/L

4.0 (3.5–5.2)

4.1 (3.9–4.8)

4.3 (3.8–4.9)

0.675

 Platelets, 103/uL

88 (68–128)

102 (49–152)

87 (53–140)

0.945

 Lactate dehydrogenase (n = 152), IU/L

2256 (1531–4350)

1451 (799–4442)

1498 (945–2512)

0.276

 Plasma hemoglobin (n = 50), mg/dL

48.9 (42.7 – NA)

13.6 (9.8–22.6)

18.5 (13.3–31.3)

0.090

  1. CRRT continuous renal replacement therapy, CVVH continuous venovenous hemofiltration, CVVHDF continuous venovenous hemodiafiltration
  2. Superscripts †, ‡ indicate significant differences (p < 0.05) between the no line group and the double line group, and the single line group and the double line group, respectively
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us